Business Wire

Altium and AWS Collaborate to Advance Electronic Design

17.3.2021 11:30:00 EET | Business Wire | Press release

Share

Altium LLC is committed to bringing transformation to the electronics industry through a digital platform that connects design to the supply chain and the manufacturing floor. To achieve this goal, Altium selected Amazon Web Services (AWS) to host Altium 365, the cloud platform for collaborative PCB design and realization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005247/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Altium selected Amazon Web Services (AWS) to host Altium 365, the first cloud-based platform to streamline the development and realization of printed circuit boards (PCBs). Teams can organize designs, libraries and participants in one place, and share links to their designs for easy, real-time collaboration. Designs are accessible at any time, on any device, anywhere, thanks to AWS's proven global infrastructure. (Graphic: Altium LLC)

The Altium 365 cloud-based platform and Altium Designer elevates PCB design by creating seamless collaboration points across the development process, making it the most connected design experience in the industry. This streamlines the product development process and allows engineers and designers to create smart and connected electronic products faster than ever before.

With Altium 365, users can bring together the stakeholders and participants in the electronic design process—even if they do not have Altium Designer—while keeping IPs secure and designs under control. Altium 365 provides a completely new way to share, visualize, and mark-up PCB designs for all stakeholders involved, from design managers to manufacturers, while allowing other designers to connect to the same PCB design with Altium Designer to author changes.

“AWS is central to Altium 365’s success to keep the platform, customers’ designs, and data secure, available and accessible,” said Greg Bellasis, Altium’s Director of Cybersecurity. “A broad portfolio of AWS services and the collaboration with their enterprise support team helps us achieve this goal to ensure ongoing stability, security, and reliability for our users to connect with anyone, from anywhere, in any time zone and from any web-enabled device to get their job done.”

Teams can organize designs, libraries, and participants in one place, and share links to their designs for easy, real-time collaboration. Designs are accessible at any time, on any device, anywhere, thanks to AWS’s proven global infrastructure. By leveraging CAD-specific intelligence, design data can be stored in a way that makes projects, files and version history accessible and easy to navigate on the web.

As Michael Weston, Lead Engineer in Kinetic Vision’s Product Design and Development Group, explains, “We switched over to Altium 365 in January 2020 because we needed a more stable platform for our data and collaboration methods compared to the local methods we were using, but with the COVID-19 situation, the platform became even more essential because our team members could continue to work remotely. Altium 365 has given us more power to create brilliant work—no matter where our team is working from.”

“There’s a broad recognition that cloud is a more secure place to do collaborative projects than traditional on-premises infrastructures,” said David Pellerin, head of Worldwide Business Development for Infotech/Semiconductor at AWS. “By using the cloud to secure their most sensitive data and improve efficiencies and maximize collaboration, Altium and their customers can free up developers and engineers to focus on innovation.”

By combining the flexibility of sharing and collaboration in the cloud with the power of desktop PCB design software, Altium is making a big leap towards modernizing and transforming the way the electronics industry meets the growing demand for smart and connected products.

ABOUT ALTIUM

Altium LLC, a global software company headquartered in San Diego, California, is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Masha V. Petrova
VP, Brand and Communications
pr@altium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye